Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure - Scorecard - MDSpire

Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure

  • By

  • Ramzi Ibrahim

  • Luke Dreher

  • Hussein Abdul Nabi

  • Juan Maria Farina

  • Eiad Habib

  • Hoang Nhat Pham

  • Min Choon Tan

  • Hussein A. Noureldine

  • Sammudeen Ibrahim

  • Mayurkumar Bhakta

  • Kwan Lee

  • Dan Sorajja

  • Win-Kuang Shen

  • Luis R. Scott

  • Chadi Ayoub

  • Reza Arsanjani

  • Hicham Z. El Masry

  • May 26, 2026

  • 0 min

Share

Clinical Scorecard: Association of Lipoprotein(a) Levels with Treated Ventricular Arrhythmia Risk in Heart Failure Patients

At a Glance

CategoryDetail
Condition
Key MechanismsElevated lipoprotein(a) [Lp(a)] is associated with adverse myocardial remodeling and increased risk of ventricular arrhythmias. [Source needed]
Target Population
Care Setting

Key Highlights

  • No significant difference in all-cause mortality between elevated and lower Lp(a) groups based on study findings.

Guideline-Based Recommendations

Diagnosis

    Management

    • C
    • o
    • n
    • s
    • i
    • d
    • e
    • r
    • I
    • C
    • D
    • i
    • m
    • p
    • l
    • a
    • n
    • t
    • a
    • t
    • i
    • o
    • n
    • f
    • o
    • r
    • p
    • a
    • t
    • i
    • e
    • n
    • t
    • s
    • w
    • i
    • t
    • h
    • e
    • l
    • e
    • v
    • a
    • t
    • e
    • d
    • L
    • p
    • (
    • a
    • )
    • a
    • t
    • r
    • i
    • s
    • k
    • f
    • o
    • r
    • v
    • e
    • n
    • t
    • r
    • i
    • c
    • u
    • l
    • a
    • r
    • a
    • r
    • r
    • h
    • y
    • t
    • h
    • m
    • i
    • a
    • s
    • .
    • [
    • S
    • o
    • u
    • r
    • c
    • e
    • n
    • e
    • e
    • d
    • e
    • d
    • ]

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with HFrEF and documented Lp(a) levels undergoing ICD therapy.

        Elevated Lp(a) may identify patients at higher risk for treated ventricular arrhythmias.

        Clinical Best Practices

        • Utilize Lp(a) levels as a biomarker for assessing arrhythmia risk in HFrEF patients. [Source needed]
        • Implement appropriate ICD programming based on individual patient risk profiles. [Source needed]

        Related Resources & Content

        Original Source(s)

        Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure

        • by Ramzi Ibrahim, Luke Dreher, Hussein Abdul Nabi, Juan Maria Farina, Eiad Habib, Hoang Nhat Pham, Min Choon Tan, Hussein A. Noureldine, Sammudeen Ibrahim, Mayurkumar Bhakta, Kwan Lee, Dan Sorajja, Win-Kuang Shen, Luis R. Scott, Chadi Ayoub, Reza Arsanjani, Hicham Z. El Masry

        • May 26, 2026

        Related Content

        Role of psychological resilience and psychological distress in linking fear of disease progression to quality of life in chronic heart failure: a cross-sectional serial mediation analysis

        Functional consequences of diminished myocardial oxygen delivery per beat in experimental heart failure

        Corvad as a bridge to LVAD implantation in end-stage heart disease complicated by cardiogenic shock: a three-case series